BioCentury
ARTICLE | Company News

Alseres, Navidea deal

June 8, 2015 7:00 AM UTC

The partners terminated a 2012 deal granting Navidea exclusive, worldwide rights to develop and commercialize Altropane ( NAV5001). Navidea will be eligible to receive a milestone payment upon FDA ap...